HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
保健科学院・保健科学研究院  >
雑誌発表論文等  >

Prediction of response to remission induction therapy by gene expression profiling of peripheral blood in Japanese patients with microscopic polyangiitis

この資料はクリエイティブ・コモンズ・ライセンスの下で公開されています。

フルテキスト
Arthritis Res Ther_19_117.pdf812.72 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/66002

タイトル: Prediction of response to remission induction therapy by gene expression profiling of peripheral blood in Japanese patients with microscopic polyangiitis
著者: Ishizu, Akihiro 著作を一覧する
Tomaru, Utano 著作を一覧する
Masuda, Sakiko 著作を一覧する
Sada, Ken-ei 著作を一覧する
Amano, Koichi 著作を一覧する
Harigai, Masayoshi 著作を一覧する
Kawaguchi, Yasushi 著作を一覧する
Arimura, Yoshihiro 著作を一覧する
Yamagata, Kunihiro 著作を一覧する
Ozaki, Shoichi 著作を一覧する
Dobashi, Hiroaki 著作を一覧する
Homma, Sakae 著作を一覧する
Okada, Yasunori 著作を一覧する
Sugiyama, Hitoshi 著作を一覧する
Usui, Joichi 著作を一覧する
Tsuboi, Naotake 著作を一覧する
Matsuo, Seiichi 著作を一覧する
Makino, Hirofumi 著作を一覧する
キーワード: Microscopic polyangiitis
Prediction of response to treatment
Gene profiling
Peripheral blood
発行日: 2017年 5月31日
出版者: BioMed Central
誌名: Arthritis Research & Therapy
巻: 19
号: 1
出版社 DOI: 10.1186/s13075-017-1328-7
抄録: Background: Microscopic polyangiitis (MPA), which is classified as an anti-neutrophil cytoplasmic antibody (ANCA)- associated small vessel vasculitis, is one of the most frequent primary vasculitides in Japan. We earlier nominated 16 genes (IRF7, IFIT1, IFIT5, OASL, CLC, GBP-1, PSMB9, HERC5, CCR1, CD36, MS4A4A, BIRC4BP, PLSCR1, DEFA1/DEFA3, DEFA4, and COL9A2) as predictors of response to remission induction therapy against MPA. The aim of this study is to determine the accuracy of prediction using these 16 predictors. Methods: Thirty-nine MPA patients were selected randomly and retrospectively from the Japanese nationwide RemIT-JAV-RPGN cohort and enrolled in this study. Remission induction therapy was conducted according to the Guidelines of Treatment for ANCA-Associated Vasculitis published by the Ministry of Health, Labour, and Welfare of Japan. Response to remission induction therapy was predicted by profiling the altered expressions of the 16 predictors between the period before and 1 week after the beginning of treatment. Remission is defined as the absence of clinical manifestations of active vasculitis (Birmingham Vasculitis Activity Score 2003: 0 or 1 point). Persistent remission for 18 months is regarded as a “good response,” whereas no remission or relapse after remission is regarded as a “poor response.” Results: “Poor” and “good” responses were predicted in 7 and 32 patients, respectively. Five out of 7 patients with “poor” prediction and 1 out of 32 patients with “good” prediction experienced relapse after remission. One out of 7 patients with “poor” prediction was not conducted to remission. Accordingly, the sensitivity and specificity to predict poor response was 85.7% (6/7) and 96.9% (31/32), respectively. Conclusions: Response to remission induction therapy can be predicted by monitoring the altered expressions of the 16 predictors in the peripheral blood at an early point of treatment in MPA patients
資料タイプ: article
URI: http://hdl.handle.net/2115/66002
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 石津 明洋

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学